Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
accepted:
17
04
2023
medline:
2
6
2023
pubmed:
5
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
Programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy is used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), regardless of age. We examined the role of the Geriatric 8 (G8) screening tool for evaluating treatment outcomes in patients with ES-SCLC treated with PD-L1 inhibitor plus platinum-etoposide chemotherapy as first-line therapy. Between September 2019 and October 2021, we prospectively evaluated patients with ES-SCLC treated with immunochemotherapy at ten institutions in Japan. The G8 score was assessed before treatment initiation. We evaluated 44 patients with ES-SCLC. Patients with G8 score > 11 had longer overall survival (OS) than those with G8 score ≤ 11 (not reached versus 8.3 months; log-rank test, p = 0.005). In univariate and multivariate analyses, G8 score > 11 [hazard ratio (HR) 0.34; 95% confidence interval (CI) 0.15-0.75; p = 0.008 and HR 0.34; 95% CI 0.14-0.82; p = 0.02, respectively) and performance status (PS) of 2 (HR 5.42; 95% CI 2.08-14.2; p < 0.001 and HR 6.94; 95% CI 2.25-21.4; p < 0.001, respectively) were independent prognostic factors for OS. Among patients with good PS (0 or 1), the OS in patients with G8 score > 11 was significantly longer than that in patients with G8 score ≤ 11 (not reached versus 12.3 months; log-rank test, p = 0.02). G8 score evaluation before treatment initiation was useful as a prognostic factor for ES-SCLC patients who received PD-L1 inhibitors and platinum-etoposide chemotherapy, even with good PS.
Sections du résumé
BACKGROUND
Programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy is used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), regardless of age.
OBJECTIVE
We examined the role of the Geriatric 8 (G8) screening tool for evaluating treatment outcomes in patients with ES-SCLC treated with PD-L1 inhibitor plus platinum-etoposide chemotherapy as first-line therapy.
PATIENTS AND METHODS
Between September 2019 and October 2021, we prospectively evaluated patients with ES-SCLC treated with immunochemotherapy at ten institutions in Japan. The G8 score was assessed before treatment initiation.
RESULTS
We evaluated 44 patients with ES-SCLC. Patients with G8 score > 11 had longer overall survival (OS) than those with G8 score ≤ 11 (not reached versus 8.3 months; log-rank test, p = 0.005). In univariate and multivariate analyses, G8 score > 11 [hazard ratio (HR) 0.34; 95% confidence interval (CI) 0.15-0.75; p = 0.008 and HR 0.34; 95% CI 0.14-0.82; p = 0.02, respectively) and performance status (PS) of 2 (HR 5.42; 95% CI 2.08-14.2; p < 0.001 and HR 6.94; 95% CI 2.25-21.4; p < 0.001, respectively) were independent prognostic factors for OS. Among patients with good PS (0 or 1), the OS in patients with G8 score > 11 was significantly longer than that in patients with G8 score ≤ 11 (not reached versus 12.3 months; log-rank test, p = 0.02).
CONCLUSIONS
G8 score evaluation before treatment initiation was useful as a prognostic factor for ES-SCLC patients who received PD-L1 inhibitors and platinum-etoposide chemotherapy, even with good PS.
Identifiants
pubmed: 37145245
doi: 10.1007/s40266-023-01034-4
pii: 10.1007/s40266-023-01034-4
doi:
Substances chimiques
Etoposide
6PLQ3CP4P3
Immune Checkpoint Inhibitors
0
CD274 protein, human
0
B7-H1 Antigen
0
Platinum
49DFR088MY
Banques de données
UMIN-CTR
['UMIN000044048']
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
563-571Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44. https://doi.org/10.1200/JCO.2005.04.4859 .
doi: 10.1200/JCO.2005.04.4859
pubmed: 17008692
Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–37. https://doi.org/10.1038/nrc.2017.87 .
doi: 10.1038/nrc.2017.87
pubmed: 29077690
Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7:69–79. https://doi.org/10.21037/tlcr.2018.01.16 .
doi: 10.21037/tlcr.2018.01.16
pubmed: 29535913
pmcid: 5835595
Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664–72. https://doi.org/10.1002/cncr.29098 .
doi: 10.1002/cncr.29098
pubmed: 25336398
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9. https://doi.org/10.1056/NEJMoa1809064 .
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619–30. https://doi.org/10.1200/JCO.20.01055 .
doi: 10.1200/JCO.20.01055
pubmed: 33439693
pmcid: 8078320
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. https://doi.org/10.1016/S0140-6736(19)32222-6 .
doi: 10.1016/S0140-6736(19)32222-6
pubmed: 31590988
Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in elderly patients. Cancer. 2010;116:1192–200. https://doi.org/10.1002/cncr.24833 .
doi: 10.1002/cncr.24833
pubmed: 20082450
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H, et al. Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. Cancer Med. 2023;12:73–83. https://doi.org/10.1002/cam4.4938 .
doi: 10.1002/cam4.4938
pubmed: 35699088
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, et al. Efficacy and safety of programmed death-ligand 1 inhibitor plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC: a prospective observational study. JTO Clin Res Rep. 2022;3:100353. https://doi.org/10.1016/j.jtocrr.2022.100353 .
doi: 10.1016/j.jtocrr.2022.100353
pubmed: 35789793
pmcid: 9250020
Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, et al. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer. 2021;161:26–33. https://doi.org/10.1016/j.lungcan.2021.08.015 .
doi: 10.1016/j.lungcan.2021.08.015
pubmed: 34500218
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595–603. https://doi.org/10.1200/JCO.2013.54.8347 .
doi: 10.1200/JCO.2013.54.8347
pubmed: 25071125
pmcid: 4876338
Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72. https://doi.org/10.1093/annonc/mdr587 .
doi: 10.1093/annonc/mdr587
pubmed: 22250183
Takahashi M, Takahashi M, Komine K, Yamada H, Kasahara Y, Chikamatsu S, et al. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: a retrospective, single institutional study. PLoS ONE. 2017;12:e0179694. https://doi.org/10.1371/journal.pone.0179694 .
doi: 10.1371/journal.pone.0179694
pubmed: 28640844
pmcid: 5480957
Jespersen E, Winther SB, Minet LR, Möller S, Pfeiffer P. Frailty screening for predicting rapid functional decline, rapid progressive disease, and shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy—a prospective, clinical study. J Geriatr Oncol. 2021;12:578–84. https://doi.org/10.1016/j.jgo.2020.10.007 .
doi: 10.1016/j.jgo.2020.10.007
pubmed: 33830020
van Walree IC, Scheepers E, van Huis-Tanja L, Emmelot-Vonk MH, Bellera C, Soubeyran P, et al. A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. J Geriatr Oncol. 2019;10:847–58. https://doi.org/10.1016/j.jgo.2019.04.016 .
doi: 10.1016/j.jgo.2019.04.016
pubmed: 31078444
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, et al. Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology. 2021;10:1950411. https://doi.org/10.1080/2162402X.2021.1950411 .
doi: 10.1080/2162402X.2021.1950411
pubmed: 34290909
pmcid: 8274442
Shiotsu S, Yoshimura A, Yamada T, Morimoto K, Tsuchiya M, Yoshioka H, et al. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: a prospective observational study. Front Oncol. 2022;12:904644. https://doi.org/10.3389/fonc.2022.904644 .
doi: 10.3389/fonc.2022.904644
pubmed: 36158655
pmcid: 9504658
Youn B, Trikalinos NA, Mor V, Wilson IB, Dahabreh IJ. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer. 2020;126:978–85. https://doi.org/10.1002/cncr.32624 .
doi: 10.1002/cncr.32624
pubmed: 31943163
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92. https://doi.org/10.1056/NEJMoa1801005 .
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Agemi Y, Shimokawa T, Sasaki J, Miyazaki K, Misumi Y, Sato A, et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS ONE. 2019;14:e0210499. https://doi.org/10.1371/journal.pone.0210499 .
doi: 10.1371/journal.pone.0210499
pubmed: 30653558
pmcid: 6336333
Schulkes KJG, Souwer ETD, van Elden LJR, Codrington H, van der Sar-van der Brugge S, Lammers JJ, et al. Prognostic value of geriatric 8 and identification of seniors at risk for hospitalized patients screening tools for patients with lung cancer. Clin Lung Cancer. 2017;18:660-666.e1. https://doi.org/10.1016/j.cllc.2017.02.006 .
doi: 10.1016/j.cllc.2017.02.006
pubmed: 28320638
Couderc AL, Tomasini P, Nouguerède E, Rey D, Correard F, Montegut C, et al. Older patients treated for lung and thoracic cancers: unplanned hospitalizations and overall survival. Clin Lung Cancer. 2021;22:e405–14. https://doi.org/10.1016/j.cllc.2020.06.004 .
doi: 10.1016/j.cllc.2020.06.004
pubmed: 32665168
Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640–9. https://doi.org/10.1056/NEJMoa1916623 .
doi: 10.1056/NEJMoa1916623
pubmed: 32786189
pmcid: 8577315
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95. https://doi.org/10.1016/S1470-2045(10)70218-7 .
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
Friedlaender A, Liu SV, Passaro A, Metro G, Banna G, Addeo A. The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors. Clin Lung Cancer. 2020;21:e539–43. https://doi.org/10.1016/j.cllc.2020.04.006 .
doi: 10.1016/j.cllc.2020.04.006
pubmed: 32499210
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, et al. Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival. Thorac Cancer. 2022;13:2776–85. https://doi.org/10.1111/1759-7714.14621 .
doi: 10.1111/1759-7714.14621
pubmed: 36062426
pmcid: 9527159